Live Analyst Rating Changes 1525 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/John Ransom
RJ
John Ransom
Wall Street Analyst
★★★☆☆
#930
on 13Foresight · ranked by our own returns
59%
Success Rate
+14.1%
Average Return
26 of 44 calls profitable · +0.9% vs benchmark
🔒 5-year track record is Pro. Showing 1-year — upgrade.
📈 Across the calls we could measure, roughly 59% of John Ransom's ratings turned a profit when each position was held for 1 year — averaging +14.1% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

28 Buy 2 Hold 2 Sell
John's Stock Coverage 44 ratings · 2026-06-19
Company Date Position Consensus Price Target 1-Yr Return
LMRI
Lumexa Imaging Holdings, Inc.
Jun 18, 2026 BUY Strong Buy
+100.8% avg upside
8 analysts
$17.00
80.68% Upside
·
ALHC
Alignment Healthcare
May 07, 2026 BUY Strong Buy
+1.8% avg upside
19 analysts
$22.00
0.66% Upside
+7.7%
ADUS
Addus Homecare
May 06, 2026 BUY Strong Buy
+35.9% avg upside
18 analysts
-3.3%
ACHC
Acadia Healthcare
May 04, 2026 BUY Strong Buy
+57.2% avg upside
17 analysts
$39.00
56.72% Upside
-15.1%
HUM
Humana
May 01, 2026 BUY Buy
-11.2% avg upside
34 analysts
$260.00
27.87% Downside
+54.9%
UHS
Universal Health
Apr 29, 2026 HOLD Buy
+50.4% avg upside
22 analysts
-15.8%
UNH
UnitedHealth
Apr 22, 2026 BUY Strong Buy
+2.4% avg upside
35 analysts
$370.00
7.74% Downside
+16.0%
AVAH
Aveanna Healthcare Holdings
Mar 20, 2026 BUY Buy
+16.7% avg upside
17 analysts
$13.00
66.81% Upside
+15.3%
CYH
Community Health
Feb 23, 2026 SELL Sell
+44.8% avg upside
18 analysts
+15.3%
OSCR
Oscar Health
Feb 12, 2026 BUY Buy
-34.1% avg upside
15 analysts
$18.00
36.65% Downside
+106.1%
RDNT
Radnet
Dec 15, 2025 BUY Strong Buy
+50.1% avg upside
10 analysts
$95.00
76.87% Upside
-22.1%
CI
Cigna
Nov 03, 2025 BUY Strong Buy
+23.8% avg upside
29 analysts
$350.00
25.27% Upside
+12.7%
THC
Tenet Healthcare
Oct 29, 2025 BUY Strong Buy
+25.2% avg upside
26 analysts
$250.00
44.86% Upside
-14.6%
PHR
Phreesia
Sep 05, 2025 BUY Strong Buy
+82.2% avg upside
21 analysts
$33.00
251.78% Upside
-68.8%
GDRX
GoodRx Holdings
Aug 07, 2025 BUY Buy
+387.3% avg upside
28 analysts
$5.00
87.97% Upside
-24.8%
SCI
Service International
Aug 04, 2025 BUY Strong Buy
+31.6% avg upside
8 analysts
$90.00
23.98% Upside
-5.8%
GRDN
Guardian Pharmacy Services, Inc. Class A
May 14, 2025 BUY Strong Buy
-1.0% avg upside
7 analysts
$28.00
33.94% Downside
+50.4%
EHC
Encompass Health
Apr 28, 2025 BUY Strong Buy
+13.4% avg upside
22 analysts
$130.00
32.61% Upside
-11.2%
URGN
Urogen Pharma
Mar 11, 2025 BUY Strong Buy
+13.4% avg upside
16 analysts
$36.00
7.22% Upside
+74.1%
CVS
CVS Health
Feb 18, 2025 BUY Strong Buy
+3.1% avg upside
38 analysts
$75.00
23.67% Downside
+23.1%
HCA
HCA Healthcare
Nov 22, 2024 HOLD Buy
+14.2% avg upside
35 analysts
+52.0%
AIRS
Airsculpt Technologies
May 10, 2024 HOLD Hold
-3.9% avg upside
6 analysts
-36.9%
HCAT
Health Catalyst
May 10, 2023 HOLD Buy
+215.1% avg upside
15 analysts
-35.0%
HSTM
HealthStream
Apr 27, 2021 HOLD Buy
+17.0% avg upside
8 analysts
-20.6%
CAH
Cardinal Health
Mar 12, 2021 HOLD Strong Buy
-12.8% avg upside
29 analysts
-5.0%
DVA
DaVita
Feb 11, 2021 HOLD Hold
-23.2% avg upside
17 analysts
-1.5%
COR
Cencora
Feb 04, 2021 HOLD Buy
+14.6% avg upside
43 analysts
+29.4%
MCK
McKesson
Feb 02, 2021 HOLD Strong Buy
-2.2% avg upside
27 analysts
+44.5%
TRUP
Trupanion
Feb 14, 2020 HOLD Strong Buy
+73.5% avg upside
19 analysts
+36.7%
ABT
Abbott Laboratories
Dec 19, 2018 BUY Strong Buy
+31.2% avg upside
35 analysts
+28.7%
IDXX
Idexx Laboratories
Aug 17, 2018 HOLD Buy
+29.2% avg upside
17 analysts
+13.1%
SGRY
Surgery Partners
Aug 09, 2018 HOLD Strong Buy
+69.2% avg upside
18 analysts
-61.9%
MD
Pediatrix Medical Group
Aug 06, 2018 HOLD Buy
-11.2% avg upside
14 analysts
-55.8%
ICUI
ICU Medical
Aug 01, 2018 BUY Strong Buy
+15.2% avg upside
9 analysts
-12.9%
ELV
Elevance Health
May 10, 2018 HOLD Strong Buy
+10.8% avg upside
32 analysts
+20.2%
VRTX
Vertex Pharmaceuticals
May 01, 2018 BUY Strong Buy
-2.7% avg upside
61 analysts
$193.00
57.34% Downside
+13.2%
NEO
NeoGenomics
Mar 07, 2018 BUY Strong Buy
+40.2% avg upside
17 analysts
$10.00
10.25% Downside
+116.7%
QDEL
QuidelOrtho
Mar 01, 2018 BUY Buy
+185.5% avg upside
13 analysts
$55.00
302.42% Upside
+59.0%
TFX
Teleflex
Oct 02, 2017 BUY Buy
+42.3% avg upside
19 analysts
$280.00
120.43% Upside
+8.8%
MOH
Molina Healthcare
Aug 23, 2017 HOLD Buy
+13.8% avg upside
25 analysts
+130.7%
LH
Labcorp Holdings
Jul 31, 2017 BUY Strong Buy
+1.8% avg upside
36 analysts
$185.00
27.74% Downside
+10.3%
SNDA
Sonida Senior Living
Nov 15, 2016 BUY Buy
+150.0% avg upside
12 analysts
$22.00
38.74% Downside
+5.4%
CSV
Carriage Services
Oct 26, 2016 BUY Strong Buy
+40.5% avg upside
6 analysts
$28.00
26.54% Downside
+8.0%
ACAD
ACADIA Pharmaceuticals
Feb 23, 2016 BUY Strong Buy
+66.0% avg upside
42 analysts
$75.00
246.84% Upside
+95.9%
🔒 39 more ratings — with price targets, crowd consensus and our measured returns.
Free account unlocks every analyst's full coverage table.
John Ransom — Frequently Asked Questions
How accurate are John Ransom's stock ratings?
Based on the calls 13Foresight could measure, about 59% of John's ratings were profitable over a one-year hold, with an average return of +14.1% per rating, or +0.9% versus the S&P 500. We score every analyst the same way, from historical prices.
How is John ranked on 13Foresight?
John Ransom is currently ranked #930 with a 3-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does John cover?
John most recently has ratings on LMRI, ALHC, ADUS, ACHC, HUM, UHS, UNH, AVAH, CYH, OSCR, RDNT, CI and 32 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.